HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.

AuthorsA Italiano, C Delcambre, I Hostein, A L Cazeau, M Marty, A Avril, J-M Coindre, B Bui
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 21 Issue 5 Pg. 1135-7 (May 2010) ISSN: 1569-8041 [Electronic] England
PMID20215136 (Publication Type: Letter)
Chemical References
  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • temsirolimus
  • MTOR protein, human
  • Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases
  • Sirolimus
Topics
  • Female
  • Heart Neoplasms (drug therapy, metabolism, secondary)
  • Humans
  • Intracellular Signaling Peptides and Proteins (antagonists & inhibitors, metabolism)
  • Lung Neoplasms (drug therapy, metabolism, secondary)
  • Perivascular Epithelioid Cell Neoplasms (drug therapy, metabolism, pathology)
  • Protein Kinase Inhibitors (therapeutic use)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors, metabolism)
  • Sirolimus (analogs & derivatives, therapeutic use)
  • TOR Serine-Threonine Kinases
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Uterine Neoplasms (drug therapy, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: